Renovaro Inc. (NASDAQ:RENB - Get Free Report)'s share price was up 0.1% during mid-day trading on Tuesday . The company traded as high as $0.32 and last traded at $0.31. Approximately 961,250 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 1,611,336 shares. The stock had previously closed at $0.31.
Renovaro Price Performance
The business's 50 day moving average is $0.32 and its 200-day moving average is $0.52. The company has a market cap of $53.17 million, a PE ratio of -0.40 and a beta of 0.51.
Institutional Trading of Renovaro
Institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC purchased a new stake in shares of Renovaro during the 4th quarter worth approximately $27,000. Voya Investment Management LLC purchased a new stake in shares of Renovaro during the 4th quarter worth approximately $30,000. Price T Rowe Associates Inc. MD lifted its position in shares of Renovaro by 183.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 45,198 shares of the company's stock worth $38,000 after buying an additional 29,253 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Renovaro during the 4th quarter worth approximately $38,000. Finally, Corebridge Financial Inc. lifted its position in shares of Renovaro by 114.8% during the 4th quarter. Corebridge Financial Inc. now owns 57,495 shares of the company's stock worth $48,000 after buying an additional 30,727 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company's stock.
Renovaro Company Profile
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
See Also
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
